Core Insights - MediWound is expanding the development of EscharEx beyond venous leg ulcers (VLUs) to include diabetic foot ulcers (DFUs) and pressure ulcers, with plans to initiate a Phase II study in DFUs in the second half of 2026 [1][7] - The company reported a decline in revenue for 2025, primarily due to a U.S. government shutdown, but reaffirmed revenue guidance for the upcoming years [5][17] Company Developments - MediWound's CEO highlighted 2025 as a pivotal year, with significant growth drivers in place, particularly the ongoing Phase III VALUE trial for EscharEx targeting 216 patients across approximately 40 sites in the U.S. and Europe [3][4] - The company has completed an expanded manufacturing facility for NexoBrid, increasing production capacity sixfold, with commercial release expected pending regulatory clearance in the second half of 2026 [6][9] Financial Performance - For Q4 2025, MediWound reported revenue of $1.9 million, down from $5.8 million in the prior year, largely due to the U.S. government shutdown [11] - Full-year 2025 revenue was $17.0 million, a decrease from $20.2 million in 2024, with gross profit improving to $3.3 million (19.2% margin) [13][14] - The company ended 2025 with $53.6 million in cash, up from $43.6 million at the end of 2024, and used $21.4 million for operating activities during the year [16] Research and Collaborations - MediWound is collaborating with several advanced wound care companies, including B. Braun, to support the clinical development of EscharEx, particularly in the planned Phase II DFU study [8] - The company plans to conduct third-party market research alongside the pressure ulcer initiative to quantify the addressable market opportunity [7] Future Outlook - Management reaffirmed revenue guidance of $24 million to $26 million for 2026, $32 million to $35 million for 2027, and $50 million to $55 million for 2028, assuming continued support from BARDA and the U.S. Department of War [17][18] - The company has been awarded $18.2 million in non-dilutive funding from the U.S. Department of War to support the development of a room-temperature stable formulation for military applications [18]

Core Viewpoint - MediWound Ltd. has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025, with the SEC, highlighting its ongoing commitment to transparency and regulatory compliance [2]. Company Overview - MediWound Ltd. is a global biotechnology company specializing in enzymatic, non-surgical therapies for tissue repair [4]. - The company's FDA-approved product, NexoBrid, is used for the enzymatic removal of eschar in thermal burns and is marketed in multiple regions including the United States, European Union, and Japan [4]. - MediWound's late-stage pipeline product, EscharEx, is an investigational therapy aimed at chronic wound debridement, with the potential to set a new standard of care in wound management [4]. Annual Report Details - The annual report on Form 20-F includes audited financial statements and is available for shareholders upon request [3]. - Shareholders can request a hard copy of the annual report via email or post [3].

Core Insights - The company has successfully commissioned an expanded manufacturing facility, increasing NexoBrid production capacity sixfold to meet anticipated global demand [1] - Revenue for 2025 was impacted by the U.S. government shutdown, which delayed budget approvals and the initiation of new development service contracts [1] - The Phase III VALUE trial for EscharEx in venous leg ulcers (VLU) is advancing as planned, with the majority of clinical sites now active and enrolling [1] Strategic Developments - The strategic expansion of the EscharEx program into diabetic foot ulcers (DFU) and pressure ulcers aims to capture the three major chronic wound indications [1] - Industry validation continues to grow through research collaborations with seven market-leading wound care companies, including a new partnership with B. Braun [1] Financial Performance - Gross margin improvement in 2025 was driven by a more favorable revenue mix despite lower overall top-line results [1] - Management maintains operational resilience and discipline in Israel despite ongoing regional conflict, ensuring clinical and commercial milestones remain on track [1]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $1.9 million, down from $5.8 million in Q4 2024, primarily due to lower development services revenue linked to a U.S. government shutdown [10][11] - Gross profit for Q4 2025 was $0.3 million (14.9% of revenue), compared to $0.9 million (15.5% of revenue) in the prior year [10][11] - Full year 2025 revenue was $17 million, down from $20.2 million in 2024, attributed mainly to the U.S. government shutdown and lower product sales [11][12] - Net loss for 2025 was $23.9 million ($2.10 per share), improved from a net loss of $30.2 million ($3.03 per share) in 2024 [12][13] - Adjusted EBITDA loss for 2025 was $20.3 million, compared to a loss of $14.8 million in 2024 [13] Business Line Data and Key Metrics Changes - R&D expenses for Q4 2025 were $4.5 million, up from $3 million in Q4 2024, reflecting ongoing investment in the EscharEx VALUE phase 3 study [10][11] - SG&A expenses totaled $3.6 million in Q4 2025, down from $4 million in the same period last year, mainly due to lower marketing and share-based compensation expenses [11] - The expanded manufacturing facility for NexoBrid is now operational, increasing production capacity sixfold [8][9] Market Data and Key Metrics Changes - NexoBrid is being utilized across more than 70 burn centers in the U.S., representing the majority of Vericel's approximately 90 target accounts [9] - Recent data from the Israel Defense Forces indicated that NexoBrid was clinically applicable in 71% of war-related injuries, supporting its role in acute trauma care [9] Company Strategy and Development Direction - The company aims to advance EscharEx towards pivotal milestones and secure regulatory approvals for the expanded facility [16] - MediWound has reaffirmed its revenue guidance of $24 million-$26 million for 2026, with expectations of continued support from BARDA and the U.S. Department of Defense [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating ongoing geopolitical challenges while focusing on clinical milestones and commercial objectives [5] - The company anticipates a significant increase in revenues in the second half of 2026, driven by manufacturing capacity and BARDA revenue [83] Other Important Information - The company completed a $30 million registered direct offering and $3.5 million from Series A warrant exercises, strengthening its balance sheet [14][15] - The company is expanding its clinical program for EscharEx beyond venous leg ulcers to include diabetic foot ulcers and pressure ulcers, with studies expected to begin in the second half of 2026 [7][8] Q&A Session Summary Question: Can you review the timing of MediWound filling demand for NexoBrid over the next 12-24 months? - Management indicated that the expanded manufacturing facility is operational, with regulatory approvals expected in late 2026, and demand is larger than current manufacturing capacity [19][20] Question: Can you discuss the pressure ulcer trial and its potential market size? - Management noted that pressure ulcers are considered a significant market opportunity, and a third-party market research project will help assess the size of the addressable market [27][28] Question: What is the status of BARDA and DoD support for revenue guidance? - Management confirmed that revenue guidance includes potential contributions from BARDA and the DoD, with ongoing discussions expected to resume following the normalization of federal operations [33][34] Question: How is the supply chain for clinical studies being managed amid geopolitical tensions? - Management assured that there is sufficient EscharEx supply to support the trial for at least six months, with no anticipated supply chain issues impacting the clinical study [46] Question: What is the expected impact of the interim analysis on the VALUE trial timeline? - Management stated that the interim analysis will be conducted after 65% enrollment, with potential adjustments to sample size if necessary, which could impact the timeline [44]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $1.9 million, down from $5.8 million in Q4 2024, primarily due to lower development services revenue linked to a U.S. government shutdown [10][11] - Gross profit for Q4 2025 was $0.3 million (14.9% of revenue), compared to $0.9 million (15.5% of revenue) in the prior year [10][11] - Full year 2025 revenue was $17 million, down from $20.2 million in 2024, attributed mainly to the U.S. government shutdown and lower product sales [12] - Net loss for 2025 was $23.9 million ($2.10 per share), improved from a net loss of $30.2 million ($3.03 per share) in 2024 [13] Business Line Data and Key Metrics Changes - R&D expenses for Q4 2025 were $4.5 million, up from $3 million in Q4 2024, reflecting ongoing investment in the EscharEx VALUE Phase III study [10][11] - SG&A expenses for Q4 2025 totaled $3.6 million, down from $4 million in the same period last year, mainly due to lower marketing and share-based compensation expenses [11] - Operating loss for the year was $25.3 million, compared to $19.4 million in 2024, indicating increased investment in R&D [12] Market Data and Key Metrics Changes - The expanded manufacturing facility for NexoBrid is now operational, increasing production capacity sixfold to meet growing global demand [8] - NexoBrid is being utilized across more than 70 burn centers in the U.S., representing a significant portion of Vericel's target accounts [9] Company Strategy and Development Direction - The company aims to advance EscharEx towards pivotal milestones and secure regulatory approvals for its expanded facility, focusing on long-term value creation [16] - MediWound has reaffirmed its revenue guidance of $24 million-$26 million for 2026, with expectations of continued support from BARDA and the U.S. Department of War [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating ongoing geopolitical challenges while maintaining focus on clinical milestones and commercial objectives [5] - The company anticipates a significant increase in revenues in the second half of 2026, driven by manufacturing capacity and BARDA revenue [83] Other Important Information - The company has completed a $30 million registered direct offering and $3.5 million from Series A warrant exercises, enhancing its financial flexibility [15] - The EscharEx clinical program is expanding to include diabetic foot ulcers and pressure ulcers, with studies expected to begin in the second half of 2026 [7][8] Q&A Session Summary Question: Can you review the timing of MediWound filling demand for NexoBrid over the next 12-24 months? - Management indicated that the expanded manufacturing facility is operational, with regulatory approvals expected in late 2026, which will allow for market release of products manufactured during the validation process [19][20] Question: Can you discuss the pressure ulcer trial and its market potential? - Management acknowledged that pressure ulcers represent a significant market opportunity and that the upcoming investigator-led study will help assess the potential for EscharEx in this indication [27][28] Question: What is the status of BARDA and Department of War collaborations? - Management confirmed ongoing collaboration with BARDA and the Department of War, with expectations for continued funding and support for NexoBrid development [34] Question: How does the company plan to approach the head-to-head study? - The head-to-head study against collagenase is planned to support future market access discussions, with a start date anticipated in mid-2026 [70] Question: What is the expected revenue guidance for 2026? - Management expressed confidence in achieving the revenue guidance of $24 million-$26 million, although specific splits between sources were not disclosed [48]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $1.9 million, a decrease from $5.8 million in Q4 2024, primarily due to lower development services revenue linked to a U.S. government shutdown [9][10] - Gross profit for Q4 2025 was $0.3 million (14.9% of revenue), compared to $0.9 million (15.5% in Q4 2024) [9][10] - Full year 2025 revenue was $17 million, down from $20.2 million in 2024, attributed mainly to the U.S. government shutdown and lower product sales [10][11] - Net loss for 2025 was $23.9 million ($2.10 per share), an improvement from a net loss of $30.2 million ($3.03 per share) in 2024 [12] Business Line Data and Key Metrics Changes - R&D expenses for Q4 2025 were $4.5 million, up from $3 million in Q4 2024, reflecting ongoing investment in the EscharEx VALUE phase 3 study [10] - SG&A expenses for Q4 2025 totaled $3.6 million, down from $4 million in the same period last year, mainly due to lower marketing and share-based compensation expenses [10] - The expanded manufacturing facility for NexoBrid is now operational, increasing production capacity sixfold to meet growing global demand [6][8] Market Data and Key Metrics Changes - Enrollment in the global phase 3 VALUE study for EscharEx is ongoing, targeting 216 patients across approximately 40 sites in the U.S. and Europe, with completion expected by year-end 2026 [5][6] - NexoBrid is being utilized across more than 70 burn centers in the U.S., representing the majority of Vericel's target accounts [6][8] Company Strategy and Development Direction - The company aims to advance EscharEx towards pivotal milestones and secure regulatory approvals for the expanded manufacturing facility, focusing on long-term value creation [15] - MediWound is expanding the EscharEx clinical program to include diabetic foot ulcers and pressure ulcers, aligning with both the FDA and EMA [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating ongoing geopolitical challenges and emphasized a focus on clinical milestones and commercial objectives [4] - The company reaffirmed its revenue guidance of $24 million-$26 million for 2026, with expectations of continued support from BARDA and the U.S. Department of Defense [14][15] Other Important Information - The company completed a $30 million registered direct offering and $3.5 million from Series A warrant exercises, strengthening its balance sheet [12][13] - The company plans to prioritize support for national preparedness initiatives, including stockpiling and collaboration with military and emergency response systems [8] Q&A Session Summary Question: Can you review the timing of MediWound filling demand for NexoBrid over the next 12-24 months? - The expanded manufacturing facility is operational, with a sixfold increase in capacity, and regulatory approvals are expected in late 2026, which will allow for market release [18] Question: Can you discuss the pressure ulcer trial and its potential market size? - The pressure ulcer indication is expected to be significant, potentially representing a third of the business, but further market research is needed to quantify the opportunity [26][27] Question: How much of the 2026 revenue guidance is based on new contracts versus existing awards? - The revenue guidance includes potential contributions from BARDA and the U.S. Department of Defense, but specific splits were not disclosed [30][33] Question: What is the status of the head-to-head study? - The head-to-head study is planned to start around mid-2026, which will help determine the pricing of EscharEx [70][71] Question: Will the interim analysis for the VALUE study be completed by year-end? - The interim analysis is expected to be completed by year-end, with no specific enrollment numbers shared to protect study integrity [72][77]

MediWound (MDWD) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +14.07%. A quarter ago, it was expected that this developer of treatments for burns and hard-to-heal wounds would post a loss of $0.81 per share when it actually produced a loss of $0.24, delivering a surprise of +70.37%.Over ...

Regulatory Compliance - Compliance with healthcare laws is critical, as violations may lead to significant civil, criminal, and administrative penalties[102]. - Violations of the federal Anti-Kickback Statute can result in civil monetary penalties and exclusion from government healthcare programs[103]. - The federal False Claims Act allows for treble damages and penalties for false claims submitted for payment, impacting financial performance[105]. - Companies may face substantial fines under the GDPR for noncompliance, with penalties up to €20 million or 4% of annual global revenues[119]. - Compliance costs related to data protection laws are expected to increase, potentially affecting financial condition[114]. - The company is subject to various state and foreign laws that may impose additional compliance obligations and costs[110]. - Increased scrutiny of business practices by regulatory authorities could lead to adverse consequences for the company[102]. - The company must ensure compliance with evolving data protection regulations to avoid negative publicity and enforcement actions[114]. - The company may incur additional costs and regulatory investigations due to new personal data export mechanisms and enforcement actions by supervisory authorities[120]. - The company is subject to the Israeli Privacy Protection Law and its regulations, which impose obligations on how personal data is processed and secured[121]. - A significant amendment to the Privacy Protection Law, effective August 14, 2025, may require the company to modify data practices and incur substantial costs[122]. - Non-compliance with the Privacy Protection Law could lead to enforcement actions, litigation, and increased costs for remedial actions[123]. - The company must comply with numerous government contracting regulations, which can complicate the retention of rights under BARDA contracts[130]. Intellectual Property - As of December 31, 2025, the company had been granted a total of over 80 patents, with 37 currently in force and 13 pending patent applications[140]. - Eleven of the currently issued NexoBrid patents expired in November 2025, while one U.S. patent for NexoBrid received a 5-year extension, expiring in 2030[146]. - The patent landscape in the biotechnology field is highly uncertain, and changes in patent laws may diminish the value and strength of the company's intellectual property[142]. - The company relies on a combination of patents, trademarks, and trade secret laws to protect its intellectual property rights, but may face challenges from competitors[139]. - The company may incur significant costs and management distraction from potential lawsuits to enforce its intellectual property rights[143]. - Unauthorized use of the company's intellectual property could adversely affect its business and demand for its products[147]. - The company may be subject to claims of infringing third-party intellectual property rights, which could result in substantial litigation costs[152]. - Effective protection of intellectual property rights may be limited in some jurisdictions, impacting the company's competitive position[145]. - The company may not be able to prevent competitors from using its technologies in jurisdictions where it lacks patent protection[145]. - The company faces risks associated with patent litigation, which could absorb significant management time and resources[155]. Financial Performance - Strengthening of the dollar could impact competitiveness in foreign markets, particularly in the Asia Pacific region[100]. - Potential delays or discontinuation of product development for NexoBrid and EscharEx could adversely affect business prospects[101]. - The company may face product liability lawsuits that could result in significant litigation costs and impact its financial condition[132]. - The company is subject to extensive environmental, health, and safety regulations, which could lead to substantial liabilities and compliance costs[133]. - Changes in tax legislation, such as the OECD's BEPS initiative, could materially affect the company's financial condition and results of operations[134]. - The market price of the company's ordinary shares may fluctuate due to various factors, including operational results and market conditions[159]. - The company is exempt from certain SEC rules and proxy requirements as a foreign private issuer, which may reduce the frequency and scope of information available to investors[169]. - Changes in the company's status as a foreign private issuer could significantly increase compliance costs and regulatory burdens[171]. - The SEC is considering revisions to the foreign private issuer definition, which could impose more stringent requirements on the company if it fails to meet new conditions[172]. - The company has received approximately $14.2 million in grants from the Israeli Innovation Authority, with an amortized liability of about $8.1 million as of December 31, 2025[192]. - As of December 31, 2025, the company accrued and paid net royalties to the IIA amounting to $2.4 million[192]. - The company is required to comply with the Encouragement of Research, Development and Technological Innovation in the Industry Law, which restricts the transfer of know-how developed with IIA funding outside of Israel[193]. - The company has not submitted applications for IIA grants since 2020 and does not plan to do so in 2026[192]. - The company may incur additional costs and risks related to compliance with environmental, social, and governance (ESG) regulations, which could adversely impact its financial condition[179]. - The intensifying effects of climate change may lead to substantial operational expenses and negatively affect profitability[180]. - The company may face adverse tax consequences if classified as a passive foreign investment company (PFIC), impacting U.S. shareholders[181]. Operational Risks - The company faces risks from IT system failures and cyberattacks, which could disrupt operations and lead to material financial impacts[124]. - Cybersecurity threats are increasing in frequency and sophistication, posing risks to the company's confidential information and operations[126]. - Political and military conditions in Israel could materially affect the company's business and operations[182]. - The company has experienced workforce disruptions due to military conflicts, which may impact product development and sales[185]. - Israeli corporate law may impede potential mergers or acquisitions, even if favorable terms are presented[188]. - The transfer of IIA-supported technology outside of Israel may incur significant penalties and increased royalties based on manufacturing volume[194]. - Shareholders' rights and responsibilities are governed by Israeli law, differing materially from U.S. corporations, including a duty to act in good faith[196]. - The quorum for ordinary shareholder meetings requires at least two shareholders holding 25% of outstanding shares, which is lower than customary for U.S. issuers[196].

Core Insights - MediWound Ltd. is advancing its Phase III VALUE trial of EscharEx as planned, with key clinical milestones expected by year-end 2026 [4][7] - The company has expanded its NexoBrid manufacturing facility, which is now operational and expected to increase production capacity sixfold, supporting anticipated global demand following regulatory approvals expected in 2026 [2][4][7] - Financial results for 2025 show a revenue decrease to $17 million from $20.2 million in 2024, primarily due to the U.S. government shutdown affecting budget approvals and new contractual agreements [15][28] Financial Performance - Fourth quarter 2025 revenue was $1.9 million, down from $5.8 million in Q4 2024, with a gross profit of $0.3 million and a gross margin of 14.9% [6][28] - For the full year 2025, the net loss was $23.9 million, or $2.10 per share, compared to a net loss of $30.2 million, or $3.03 per share, in 2024 [15][28] - Research and development expenses increased to $14.3 million in 2025 from $8.9 million in 2024, mainly due to costs associated with the EscharEx VALUE Phase III trial [15][28] Future Outlook - The company reaffirms its revenue guidance of $24–26 million for 2026, $32–35 million for 2027, and $50–55 million for 2028, assuming continued support from BARDA and the U.S. Department of War [10] - The 2028 outlook includes a potential initial contribution from EscharEx, subject to regulatory approval [10] Strategic Developments - Enrollment in the global Phase III VALUE study for venous leg ulcers is ongoing, targeting 216 patients across approximately 40 sites in the U.S. and Europe [7] - The EscharEx clinical program is expanding into two additional indications: a Phase II study in diabetic foot ulcers and an investigator-initiated trial in pressure ulcers planned for the second half of 2026 [7] - Collaborations with B. Braun and other companies are enhancing the clinical development program for EscharEx [7]

Summary of MediWound Conference Call Company Overview - **Company**: MediWound - **Key Products**: NexoBrid and EscharEx - **Market Focus**: Wound care, specifically for severe burns and chronic wounds - **Current Financials**: $54 million in cash, with a revenue-generating business in NexoBrid Industry Insights - **Total Addressable Market (TAM)**: - Severe burns in the U.S. is approximately $300 million [2] - Chronic wounds applicable to EscharEx are around 4 million, indicating a much larger market potential [5] Product Development and Clinical Trials - **NexoBrid**: - Approved for eschar removal in severe burns, with a focus on mass casualty events [5][6] - Manufacturing capacity is set to expand sixfold, with inspections by EMA and FDA planned [7][8] - **EscharEx**: - Undergoing Phase 3 trials for venous leg ulcers (VLUs) and Phase 2 for diabetic foot ulcers (DFUs) [6][9] - Expected to file for approval in 2027, with potential market entry in 2028 [11] Clinical Efficacy - **Debridement Efficiency**: - EscharEx shows 63% complete debridement within two weeks compared to 0% for SANTYL, a competitor [20] - Average time to wound bed preparation is significantly shorter with EscharEx (48.4 days) compared to SANTYL (76 days) [20] - **Market Positioning**: - EscharEx aims to capture a significant share of the chronic wound market, with projected peak sales in the U.S. reaching $831 million from a $2.5 billion TAM [20][21] Strategic Partnerships and Funding - **Collaborations**: - Partnerships with global companies to validate technology and support clinical studies [2][27] - **Government Funding**: - Initial funding for NexoBrid development has come from U.S. government sources, including the Department of Defense [5] Future Projections - **Revenue Growth**: - Projected revenue for this year is $24-$26 million, increasing to $32-$35 million next year [11][12] - Potential for higher margins (up to 65%) with increased manufacturing capacity [10] - **Market Expansion**: - Plans to expand into additional markets, including Europe and Japan, post-approval [8][10] Risks and Considerations - **Regulatory Approval**: - Success hinges on timely inspections and approvals from EMA and FDA [8][9] - **Market Competition**: - SANTYL remains a significant competitor, with established market presence and sales of over $370 million annually [18] Conclusion MediWound is positioned for significant growth in the wound care market, with promising clinical data for EscharEx and a solid foundation with NexoBrid. The company is actively expanding its manufacturing capabilities and exploring strategic partnerships to enhance its market presence.